| Status | Study |
| Active, not recruiting |
Study Name: Acalabrutinib in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL Condition: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Date: 2014-11-19 Interventions: Drug: acalabrutinib in combination with obinutuzumab |
| Withdrawn |
Study Name: Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation Condition: Prolymphocytic Leukemia Recurrent Mantle Cell Lymphoma Date: 2014-11-04 Interventions: Drug: sotrastaurin acetate Giv |
| Active, not recruiting |
Study Name: Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia Condition: Post-transplant Lymphoproliferative Disorder B-Cell Prolymphocytic Leu Date: 2014-05-30 Interventions: Drug: cyclophosphamide Given I |
| Active, not recruiting |
Study Name: ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia Condition: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Ri Date: 2014-01-06 Interventions: Drug: acalabrutinib |
| Recruiting |
Study Name: Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL Condition: Contiguous Stage II Small Lymphocytic Lymphoma Noncontiguous Stage II Small Lymphocytic Lymp Date: 2013-12-03 Interventions: Biological: MOR00208 Given by |
| Completed |
Study Name: AZD6738 First Time in Patient Multiple Ascending Dose Study Condition: 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), P Date: 2013-09-30 Interventions: Drug: Administration of AZD6738 An oral formulation of AZD6738 will be used. The starting dose of 20 mg |
| Active, not recruiting |
Study Name: PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia Condition: Prolymphocytic Leukemia Recurrent Small Lymphocytic Lymphoma Date: 2012-04-23 Interventions: Drug: ibrutinib Patients recei |
| Active, not recruiting |
Study Name: Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia Condition: Chronic Lymphocytic Leukemia Prolymphocytic Leukemia Date: 2012-01-16 Interventions: Drug: Dinaciclib Given IV |
| Completed |
Study Name: Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Condition: Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma Date: 2011-08-16 Interventions: Drug: auranofin 6 mg twice a day for a total of 12 mg total daily dose |
| Terminated |
Study Name: Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant Condition: Adult Nasal Type Extranodal NK/T-cell Lymphoma Anaplastic Large Cell Lymphoma Date: 2011-08-15 Interventions: Drug: lenalidomide Given PO |